Education
About Us
Working with TipRanks
Follow Us
Senzime AB (SE:SEZI)
:SEZI
SEZI Stock Chart & Stats
kr5.13
-kr0.14(-2.60%)
At close: 4:00 PM EST
kr5.13
-kr0.14(-2.60%)
Day’s Range― - ―
52-Week Rangekr3.60 - kr7.38
Previous CloseN/A
Volume45.51K
Average Volume (3M)534.13K
Market Cap
kr710.61M
Enterprise Valuekr746.36M
Total Cash (Recent Filing)kr73.97M
Total Debt (Recent Filing)kr26.40M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Apr 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding157,215,040
10 Day Avg. Volume328,516
30 Day Avg. Volume534,125
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSenzime's very strong recent revenue growth reflects accelerating product adoption and scaling of device and consumable sales in its B2B hospital market. Durable revenue expansion improves operating leverage potential and supports recurring consumable revenue streams over the next several quarters.
Improved Gross MarginA shift from negative to ~30% gross margin indicates structural improvement in product mix and unit economics. Higher device and consumable margins create a clearer path to operating leverage, making future profitability attainable if revenue growth sustains and fixed costs are controlled.
Low Financial LeverageVery low leverage and a substantial equity buffer provide financial flexibility to fund clinical validation, commercialization and R&D without immediate debt pressure. This structural strength reduces insolvency risk and supports strategic investments over the medium term.
Bears Say
Large Cash BurnPersistent, large negative free cash flow indicates the business is burning cash to scale and is not self-funding. Over multiple quarters this raises financing dependence, increases dilution risk, and can constrain investment cadence for commercialization and regulatory activities.
Deep Negative ProfitabilityExtremely negative net and operating margins show the cost base far exceeds current scale. Without sustained margin expansion or a faster revenue ramp, losses will persist, limiting reinvestment capacity and making long-term path to durable profitability uncertain.
Declining Equity / Dilution RiskMaterial decline in equity reflects accumulated losses and suggests prior financing or write-down effects. Continued losses and cash burn increase the likelihood of further equity raises, which would dilute existing holders and could weaken incentives for long-term investors.
Senzime AB News
SEZI FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was kr3.60 and its highest was kr7.38 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is kr710.61M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Apr 22, 2026 which is in 61 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Feb 18, 2026. The company reported -kr0.273 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.273.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -kr0.273 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.494%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in SE:SEZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
SEZI Company Deck
SEZI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth and successful market expansion, particularly in the U.S. and Asia. The launch of the next generation TetraGraph and successful capital raise were notable achievements. However, challenges such as currency effects, softer monitor sales in the U.S., and slower growth in Europe were acknowledged. Overall, the positive achievements outweighed the challenges.View all SE:SEZI earnings summariesTechnical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Integrum AB Class B
―
Sedana Medical AB
―
OssDsign AB
―